Show simple item record

dc.contributor.authorSnow, Hen_US
dc.contributor.authorHazell, Sen_US
dc.contributor.authorFrancis, Nen_US
dc.contributor.authorMohammed, Ken_US
dc.contributor.authorO'Neill, Sen_US
dc.contributor.authorDavies, Een_US
dc.contributor.authorMansfield, Den_US
dc.contributor.authorMessiou, Cen_US
dc.contributor.authorHujairi, Nen_US
dc.contributor.authorNicol, Den_US
dc.contributor.authorHarrington, Ken_US
dc.contributor.authorSmith, Men_US
dc.date.accessioned2020-07-09T12:05:36Z
dc.date.issued2020-12en_US
dc.identifier.citationJournal of cutaneous pathology, 2020, 47 (12), pp. 1115 - 1122en_US
dc.identifier.issn0303-6987en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3839
dc.identifier.eissn1600-0560en_US
dc.identifier.doi10.1111/cup.13774en_US
dc.description.abstract<h4>Background</h4>Prostate-specific membrane antigen (PSMA) is a prostatic epithelial protein that is used as a radiotracer (68Ga-PSMA-11) for prostate cancer staging. PSMA-PET/CT (positron emission tomography/computed tomography) performed for prostate cancer has been observed to detect melanoma metastases. The aim of this study was to investigate the performance of PSMA immunohistochemistry on resected melanoma metastases to explore its use as a diagnostic imaging biomarker for melanoma.<h4>Methods</h4>A total of 41 specimens with stage III/IV melanoma were stained with PSMA immunohistochemistry. All specimens required both disease and control regions. Two pathologists scored the specimens and a receiver operating characteristic (ROC) curve was plotted. Western blot and multiplex immunofluorescence were also performed.<h4>Results</h4>The area under the ROC curve was 0.82, suggesting that PSMA has excellent discriminatory power in melanoma metastases. Sensitivity is 82.9% and specificity 73.2%. Immunohistochemistry and Western blot reveal that PSMA staining in melanoma consistently and most intensely occurs in tumor neovasculature. Multiplex immunofluorescence shows that melanocytes may also weakly express PSMA.<h4>Conclusion</h4>The performance of PSMA immunohistochemistry in melanoma metastases contrasts with that reported in prostate cancer studies. This study indicates that PSMA shows promise for use as a novel biomarker in melanoma and justifies further research in the clinical setting with potential as a PET/CT radiotracer and intraoperative fluorescence marker for melanoma.en_US
dc.formatPrint-Electronicen_US
dc.format.extent1115 - 1122en_US
dc.languageengen_US
dc.language.isoengen_US
dc.rights.urihttp://www.rioxx.net/licenses/under-embargo-all-rights-reserveden_US
dc.titleProstate-specific membrane antigen expression in melanoma metastases.en_US
dc.typeJournal Article
dcterms.dateAccepted2020-05-22en_US
rioxxterms.versionofrecord10.1111/cup.13774en_US
rioxxterms.licenseref.startdate2020-12en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfJournal of cutaneous pathologyen_US
pubs.issue12en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Biology/Targeted Therapy
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Targeted Therapy
pubs.publication-statusPublisheden_US
pubs.volume47en_US
pubs.embargo.termsNot knownen_US
icr.researchteamTargeted Therapyen_US
dc.contributor.icrauthorSmith, Mylesen_US
dc.contributor.icrauthorMessiou, Christinaen_US
dc.contributor.icrauthorMansfield, Daviden_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record